Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 5/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.37 |
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.37 |
| ▸ | GMNN | O75496 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.37 |
| ▸ | BLM | P54132 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6861774 | 0.98 | TSHR (0.47) | TSHRLMNAMAPK1MAPTNPSR1 | |
| Hydrochloric Acid SCHEMBL28421869 | 0.88 | TSHR (0.50) | TSHRLMNAMAPK1MAPTNPSR1 | |
| Hydrochloric Acid SCHEMBL28066270 | 0.88 | TSHR (0.50) | TSHRLMNAMAPK1MAPTNPSR1 | |
| Hydrochloric Acid SCHEMBL727127 | 0.88 | TSHR (0.50) | TSHRLMNAMAPK1MAPTNPSR1 | |
| Hydrochloric Acid SCHEMBL28836358 | 0.88 | TSHR (0.50) | TSHRLMNAMAPK1MAPTNPSR1 | |
| Hydrochloric Acid SCHEMBL28569045 | 0.88 | TSHR (0.50) | TSHRLMNAMAPK1MAPTNPSR1 | |
| SCHEMBL9772649 | 0.86 | TSHR (0.47) | TSHRLMNAMAPK1MAPTNPSR1 | |
| SCHEMBL27943905 | 0.86 | TSHR (0.47) | TSHRLMNAMAPK1MAPTNPSR1 | |
| Bromide SCHEMBL23923504 | 0.85 | TSHR (0.46) | TSHRLMNAMAPTHSP90AA1DNM1 | |
| Bromide SCHEMBL7117275 | 0.85 | TSHR (0.46) | TSHRLMNAMAPTHSP90AA1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220266296-A1 | Methods of Photografting to Surface Metal Oxides | Orthobond Corporation | 2022-08-25 | — | — | US | claimed |
| US-20230055449-A1 | FUNCTIONAL SURFACES | ORTHOBOND CORP (US) | 2023-02-23 | — | — | US | disclosed |
| WO-2022182713-A1 | METHODS OF PHOTOGRAFTING TO SURFACE METAL OXIDES | Orthobond Corporation (US) | 2022-09-01 | — | — | WO | disclosed |
| US-20220266296-A1 | Methods of Photografting to Surface Metal Oxides | Orthobond Corporation | 2022-08-25 | — | — | US | disclosed |
| EP-3525776-B1 | SURFACES WITH OLIGOMERIC OR POLYMERIC ANTIMICROBIALS | ORTHOBOND CORP (US) | 2022-01-26 | — | — | EP | disclosed |
| US-20210352903-A1 | FUNCTIONAL SURFACES | ORTHOBOND CORP (US) | 2021-11-18 | — | — | US | disclosed |
| US-11154061-B2 | Functional surfaces | Orthobond Corporation (US) | 2021-10-26 | — | — | US | disclosed |
| US-10390533-B2 | Surfaces with oligomeric or polymeric antimicrobials | Orthobond Corporation (US) | 2019-08-27 | — | — | US | disclosed |
| EP-3525776-A1 | SURFACES WITH OLIGOMERIC OR POLYMERIC ANTIMICROBIALS | Orthobond Corporation (US) | 2019-08-21 | — | — | EP | disclosed |
| WO-2018075457-A1 | SURFACES WITH OLIGOMERIC OR POLYMERIC ANTIMICROBIALS | Orthobond Corporation (US) | 2018-04-26 | — | — | WO | disclosed |
| US-20180103642-A1 | Surfaces with Oligomeric or Polymeric Antimicrobials | Orthobond Corporation | 2018-04-19 | — | — | US | disclosed |
| US-20180103643-A1 | Functional Surfaces | Orthobond Corporation | 2018-04-19 | — | — | US | disclosed |
| US-6790877-B2 | Bonding compositions for dental use | KURARAY CO., LTD. (JP) | 2004-09-14 | — | — | US | disclosed |
| EP-0980682-B1 | Bonding compositions for dental use | KURARAY CO (JP) | 2003-11-05 | — | — | EP | disclosed |
| US-6355704-B1 | BACTERICIDE PRIMERS; BONDING TO TEETH | KURARAY CO., LTD. (JP) | 2002-03-12 | — | — | US | disclosed |
| EP-0980682-A1 | Bonding compositions for dental use | KURARAY CO., LTD. (JP) | 2000-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180103642-A1 | Surfaces with Oligomeric or Polymeric Antimicrobials | PICALM, NONO, LPO | TSHR 1455/4885LMNA 4563/4885MAPK1 4120/4885 |
| US-20230055449-A1 | FUNCTIONAL SURFACES | LPO, SELP, SIGLEC7 | TSHR 2514/4885LMNA 3860/4885MAPK1 4684/4885 |
| US-11154061-B2 | Functional surfaces | LPO, SELP, SIGLEC7 | TSHR 2514/4885LMNA 3860/4885MAPK1 4684/4885 |
| US-20210352903-A1 | FUNCTIONAL SURFACES | LPO, SELP, SIGLEC7 | TSHR 2514/4885LMNA 3860/4885MAPK1 4684/4885 |
| US-10390533-B2 | Surfaces with oligomeric or polymeric antimicrobials | PICALM, NONO, LPO | TSHR 1455/4885LMNA 4563/4885MAPK1 4120/4885 |
| US-20180103643-A1 | Functional Surfaces | LPO, SELP, SIGLEC7 | TSHR 2514/4885LMNA 3860/4885MAPK1 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.